Patents by Inventor Matthew Symonds
Matthew Symonds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230122392Abstract: One example method includes receiving a digital image of a needle core prostate biopsy, displaying, using a display device, a magnified portion of the digital image, obtaining, from a deep learning model, Gleason scores corresponding to patches of the magnified portion of the digital image, and displaying, using the display device, a superimposed overlay on the magnified portion of the digital image based on the Gleason scores and corresponding confidence values of the Gleason scores, the superimposed overlay comprising one or more outlines corresponding one or more Gleason scores associated with the magnified portion of the digital image and comprising image patches having colors based on a Gleason score of the Gleason scores corresponding to an underlying portion of the magnified portion of the digital image and a confidence value of the corresponding Gleason score.Type: ApplicationFiled: March 30, 2021Publication date: April 20, 2023Applicant: Verily Life Sciences LLCInventors: Dave STEINER, Michael TERRY, Jimbo WILSON, Andrei KAPISHNIKOV, Ben WEDIN, Kunal NAGPAL, Davis FOOTE, Carrie CAI, Liron YATZIV, Matthew SYMONDS, Craig MERMEL, Pan-Pan JIANG, Adam PEARCE, Rory SAYRES, Samantha WINTER, Cameron CHEN
-
Publication number: 20220148169Abstract: One example method for AI prediction of prostate cancer outcomes involves receiving an image of prostate tissue; assigning Gleason pattern values to one or more regions within the image using an artificial intelligence Gleason grading model, the model trained to identify Gleason patterns on a patch-by-patch basis in a prostate tissue image; determining relative areal proportions of the Gleason patterns within the image; assigning at least one of a risk score or risk group value to the image based on the determined relative areal proportions; and outputting at least one of the risk score or the risk group value.Type: ApplicationFiled: November 8, 2021Publication date: May 12, 2022Applicant: Verily Life Sciences LLCInventors: Craig Mermel, Yun Liu, Naren Manoj, Matthew Symonds, Martin Stumpe, Lily Peng, Kunal Nagpal, Ellery Wulczyn, Davis Foote, David F. Steiner, Po-Hsuan Cameron Chen
-
Publication number: 20220035600Abstract: Methods and systems that facilitate automatic generation of Application Programming Interface (API) specification from web traffic. Methods include obtaining a plurality of API requests and responses to the plurality of API requests. Methods include processing these API requests and responses to API requests to identify one or more attributes, such as, for example, variables, query parameters, response status codes, and response schemas. Methods include identifying variables using a tree data structure to represent resource paths. Methods include identifying query parameters based on resource items in resource paths. Methods include determining that the API call does not conform to the API specification by comparing one or more attributes of the API call with the attributes of the API specification.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Applicant: Google LLCInventors: Alex David Lester, Sibo Liu, Che Liu, Jared Scott Borner, Andrew Marsh Gardiner, Matthew Symonds, Kenneth Chan, Michael Christopher Yara, Terrence Li, Joy Aloysius Thomas, Sri Harsha Vardhan Reddy Chevuru, Tsenguun Tsogbadrakh
-
Patent number: 11150874Abstract: Methods and systems that facilitate automatic generation of Application Programming Interface (API) specification from web traffic. Methods include obtaining a plurality of API requests and responses to the plurality of API requests. Methods include processing these API requests and responses to API requests to identify one or more attributes, such as, for example, variables, query parameters, response status codes, and response schemas. Methods include identifying variables using a tree data structure to represent resource paths. Methods include identifying query parameters based on resource items in resource paths. Methods include determining that the API call does not conform to the API specification by comparing one or more attributes of the API call with the attributes of the API specification.Type: GrantFiled: July 23, 2020Date of Patent: October 19, 2021Assignee: Google LLCInventors: Alex David Lester, Sibo Liu, Che Liu, Jared Scott Borner, Andrew Marsh Gardiner, Matthew Symonds, Kenneth Chan, Michael Christopher Yara, Terrence Li, Joy Aloysius Thomas, Sri Harsha Vardhan Reddy Chevuru, Tsenguun Tsogbadrakh
-
Publication number: 20200364033Abstract: Methods and systems that facilitate automatic generation of Application Programming Interface (API) specification from web traffic. Methods include obtaining a plurality of API requests and responses to the plurality of API requests. Methods include processing these API requests and responses to API requests to identify one or more attributes, such as, for example, variables, query parameters, response status codes, and response schemas. Methods include identifying variables using a tree data structure to represent resource paths. Methods include identifying query parameters based on resource items in resource paths. Methods include determining that the API call does not conform to the API specification by comparing one or more attributes of the API call with the attributes of the API specification.Type: ApplicationFiled: July 23, 2020Publication date: November 19, 2020Inventors: Alex David Lester, Sibo Liu, Che Liu, Jared Scott Borner, Andrew Marsh Gardiner, Matthew Symonds, Kenneth Chan, Michael Christopher Yara, Terrence Li, Joy Aloysius Thomas, Sri Harsha Vardhan Reddy Chevuru, Tsenguun Tsogbadrakh
-
Patent number: 10747505Abstract: Methods and systems that facilitate automatic generation of Application Programming Interface (API) specification from web traffic. Methods include obtaining a plurality of API requests and responses to the plurality of API requests. Methods include processing these API requests and responses to API requests to identify one or more attributes, such as, for example, variables, query parameters, response status codes, and response schemas. Methods include identifying variables using a tree data structure to represent resource paths. Methods include identifying query parameters based on resource items in resource paths. Methods include determining that the API call does not conform to the API specification by comparing one or more attributes of the API call with the attributes of the API specification.Type: GrantFiled: May 17, 2019Date of Patent: August 18, 2020Assignee: Google LLCInventors: Alex David Lester, Sibo Liu, Che Liu, Jared Scott Borner, Andrew Marsh Gardiner, Matthew Symonds, Kenneth Chan, Michael Christopher Yara, Terrence Li, Joy Aloysius Thomas, Sri Harsha Vardhan Reddy Chevuru, Tsenguun Tsogbadrakh
-
Patent number: 7481999Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: December 3, 2004Date of Patent: January 27, 2009Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, Barbara J. Gour, James Matthew Symonds, Stephen Byers
-
Patent number: 6962969Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: December 3, 2001Date of Patent: November 8, 2005Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6830894Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1999Date of Patent: December 14, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Publication number: 20040248220Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: ApplicationFiled: January 16, 2004Publication date: December 9, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20040248219Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: ApplicationFiled: January 16, 2004Publication date: December 9, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20040229811Abstract: Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: September 3, 2003Publication date: November 18, 2004Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6797807Abstract: Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used for cancer therapy or to increase immune cell infiltration into tumors. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by the other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 29, 1999Date of Patent: September 28, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour, J. Steven Alexander
-
Patent number: 6756356Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1998Date of Patent: June 29, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6723700Abstract: Method for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequence recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: March 30, 1999Date of Patent: April 20, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6682901Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: GrantFiled: May 5, 1999Date of Patent: January 27, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Patent number: 6680175Abstract: Methods for diagnosing cancer, such as prostate, ovarian or breast cancer, as well as leukemia, are provided. Such methods may employ binding agents, such as antibodies or CAR sequences of OB-cadherin or N-cadherin, that specifically bind to OB-cadherin or N-cadherin, or polynucleotides that hybridize to a polynucleotide encoding OB-cadherin or N-cadherin. Also provided are methods for monitoring the progression of a cancer and to evaluate the metastatic potential of a cancer.Type: GrantFiled: January 20, 1999Date of Patent: January 20, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour
-
Publication number: 20030229199Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: March 21, 2003Publication date: December 11, 2003Applicant: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6638911Abstract: Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: March 27, 2000Date of Patent: October 28, 2003Assignee: Adherex Technologies Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6593297Abstract: Agents for inhibiting cancer metastasis are provided. The methods comprise administering to a patient an antimetastatic agent that comprises one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: March 8, 1999Date of Patent: July 15, 2003Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Stephen Byers, Barbara J. Gour